NEWAMSTERDAM PHARMA COMPANY's ticker is and the CUSIP is N62509109. A total of 36 filers reported holding NEWAMSTERDAM PHARMA COMPANY in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $416,250 | – | 45,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 10,473,913 | $96,883,695 | 10.83% |
| Medicxi Ventures Management (Jersey) Ltd | 2,869,565 | $26,543,476 | 8.47% |
| Frazier Life Sciences Management, L.P. | 12,131,705 | $112,218,271 | 7.45% |
| RA Capital Management | 9,000,000 | $83,250,000 | 1.64% |
| Eversept Partners, LP | 660,618 | $6,110,717 | 0.52% |
| GMT CAPITAL CORP | 1,383,800 | $12,800,150 | 0.48% |
| Parkman Healthcare Partners LLC | 249,024 | $2,303,472 | 0.42% |
| BVF INC/IL | 1,521,948 | $14,078,019 | 0.38% |
| Affinity Asset Advisors, LLC | 125,000 | $1,156,250 | 0.32% |
| VIKING GLOBAL INVESTORS LP | 8,024,565 | $74,227,226 | 0.30% |